AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 548%
Price (€) 1.67
Market Cap (€M) 61.0
Perf. 1W: -11.2%
Perf. 1M: -15.2%
Perf. 3M: -48.9%
Perf Ytd: -66.0%
10 day relative perf. to stoxx600: -11.3%
20 day relative perf. to stoxx600: -10.8%
Target Change29/11/2018

A €3.9m capital increase before year-end

Change in Target Price€ 11.1 vs 14.9-25.6%

Our target price is revised downward on the capital increase to come (December), which will lead to the issuance of c. 3.4m new shares.



Change in EPS2018 : € -0.76 vs -0.91ns
2019 : € -0.53 vs -0.73ns

Our forecasts have not changed. The higher number of shares simply implies that short-term losses are divided by a bigger number, thus the (wrong) impression on an EPS basis that forecast losses have shrunk.



Change in NAV€ 12.7 vs 17.2-26.1%

Our NAV valuation is adjusted one the one hand by a decrease in net debt thanks to the capital increase and, on the other, by the increase in the number of shares, from c.9.3m to 12.7m.



Change in DCF€ 14.8 vs 19.8-25.4%

Our forecasts remain unchanged. The higher number of shares post the capital increase and the injection of €3.9m in the balance sheet lead to a lower target price, due to the significant dilution caused by the capital increase.



Updates

28 Nov 18 Financing issue
A €3.9m capital increase

23 Oct 18 Other news/comments
Bond conversion

27 Sep 18 Earnings/sales releases
H1 18: insignificant; some more time needed to ...

05 Sep 18 Target Change
On its way to reaching the market

17 May 18 Latest
Business update

.